Logo image of ALSEN.PA

SENSORION SA (ALSEN.PA) Stock Fundamental Analysis

EPA:ALSEN - FR0012596468 - Common Stock

0.31 EUR
0 (-0.96%)
Last: 9/4/2025, 7:00:00 PM
Fundamental Rating

3

Overall ALSEN gets a fundamental rating of 3 out of 10. We evaluated ALSEN against 74 industry peers in the Biotechnology industry. The financial health of ALSEN is average, but there are quite some concerns on its profitability. ALSEN is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ALSEN had negative earnings in the past year.
ALSEN had a negative operating cash flow in the past year.
ALSEN had negative earnings in each of the past 5 years.
In the past 5 years ALSEN always reported negative operating cash flow.
ALSEN.PA Yearly Net Income VS EBIT VS OCF VS FCFALSEN.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M -25M

1.2 Ratios

ALSEN has a Return On Assets (-29.09%) which is in line with its industry peers.
ALSEN has a Return On Equity (-36.00%) which is in line with its industry peers.
Industry RankSector Rank
ROA -29.09%
ROE -36%
ROIC N/A
ROA(3y)-45.38%
ROA(5y)-34.99%
ROE(3y)-69.45%
ROE(5y)-51.62%
ROIC(3y)N/A
ROIC(5y)N/A
ALSEN.PA Yearly ROA, ROE, ROICALSEN.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300

1.3 Margins

ALSEN does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ALSEN.PA Yearly Profit, Operating, Gross MarginsALSEN.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

5

2. Health

2.1 Basic Checks

ALSEN has more shares outstanding than it did 1 year ago.
ALSEN has more shares outstanding than it did 5 years ago.
ALSEN has a better debt/assets ratio than last year.
ALSEN.PA Yearly Shares OutstandingALSEN.PA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M
ALSEN.PA Yearly Total Debt VS Total AssetsALSEN.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

ALSEN has an Altman-Z score of 2.21. This is not the best score and indicates that ALSEN is in the grey zone with still only limited risk for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 2.21, ALSEN is in the better half of the industry, outperforming 66.22% of the companies in the same industry.
ALSEN has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.
ALSEN's Debt to Equity ratio of 0.01 is fine compared to the rest of the industry. ALSEN outperforms 78.38% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z 2.21
ROIC/WACCN/A
WACCN/A
ALSEN.PA Yearly LT Debt VS Equity VS FCFALSEN.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M

2.3 Liquidity

A Current Ratio of 6.28 indicates that ALSEN has no problem at all paying its short term obligations.
ALSEN has a Current ratio of 6.28. This is amongst the best in the industry. ALSEN outperforms 83.78% of its industry peers.
ALSEN has a Quick Ratio of 6.28. This indicates that ALSEN is financially healthy and has no problem in meeting its short term obligations.
With an excellent Quick ratio value of 6.28, ALSEN belongs to the best of the industry, outperforming 86.49% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 6.28
Quick Ratio 6.28
ALSEN.PA Yearly Current Assets VS Current LiabilitesALSEN.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

4

3. Growth

3.1 Past

ALSEN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 55.21%, which is quite impressive.
EPS 1Y (TTM)55.21%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%23.9%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, ALSEN will show a very strong growth in Earnings Per Share. The EPS will grow by 41.85% on average per year.
ALSEN is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 66.11% yearly.
EPS Next Y8.33%
EPS Next 2Y18.64%
EPS Next 3Y14.47%
EPS Next 5Y41.85%
Revenue Next Year18.56%
Revenue Next 2Y30.48%
Revenue Next 3Y15.46%
Revenue Next 5Y66.11%

3.3 Evolution

ALSEN.PA Yearly Revenue VS EstimatesALSEN.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 50M 100M 150M 200M
ALSEN.PA Yearly EPS VS EstimatesALSEN.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -200 -400 -600

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ALSEN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ALSEN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ALSEN.PA Price Earnings VS Forward Price EarningsALSEN.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALSEN.PA Per share dataALSEN.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.1 0.2

4.3 Compensation for Growth

ALSEN's earnings are expected to grow with 14.47% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y18.64%
EPS Next 3Y14.47%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ALSEN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SENSORION SA

EPA:ALSEN (9/4/2025, 7:00:00 PM)

0.31

0 (-0.96%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-14 2025-03-14/amc
Earnings (Next)09-16 2025-09-16
Inst Owners53.64%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap93.20M
Analysts86.15
Price Target2.14 (590.32%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)12%
PT rev (3m)-3.08%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-3.12%
EPS NY rev (3m)-3.12%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-39.38%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.29
P/tB 1.31
EV/EBITDA N/A
EPS(TTM)-0.09
EYN/A
EPS(NY)-0.08
Fwd EYN/A
FCF(TTM)-0.07
FCFYN/A
OCF(TTM)-0.07
OCFYN/A
SpS0
BVpS0.24
TBVpS0.24
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -29.09%
ROE -36%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-45.38%
ROA(5y)-34.99%
ROE(3y)-69.45%
ROE(5y)-51.62%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 60.78%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.28
Quick Ratio 6.28
Altman-Z 2.21
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)191.05%
Cap/Depr(5y)144.18%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)55.21%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%23.9%
EPS Next Y8.33%
EPS Next 2Y18.64%
EPS Next 3Y14.47%
EPS Next 5Y41.85%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year18.56%
Revenue Next 2Y30.48%
Revenue Next 3Y15.46%
Revenue Next 5Y66.11%
EBIT growth 1Y-27.3%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year70.76%
EBIT Next 3Y13.96%
EBIT Next 5Y38.57%
FCF growth 1Y-0.44%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-1.23%
OCF growth 3YN/A
OCF growth 5YN/A